Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

ABBOTT LABORATORIES

(ABT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

ABBOTT LABORATORIES : Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant (form 8-K)

11/12/2020 | 04:07pm EST

Item 1.01. Entry into a Material Definitive Agreement.

On November 12, 2020 (the "Effective Date"), Abbott Laboratories, an Illinois corporation ("Abbott"), entered into a Five Year Credit Agreement (the "Revolving Credit Agreement") with the lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent.

The Revolving Credit Agreement provides Abbott with the ability to borrow up to $5 billion on an unsecured basis. Any borrowings under the Revolving Credit Agreement will mature and be payable on the fifth anniversary of the Effective Date. As of the date of this Current Report on Form 8-K, there are no outstanding borrowings under the Revolving Credit Agreement.

Abbott's borrowings under the Revolving Credit Agreement will bear interest, at Abbott's option, based on either a base rate or a Eurodollar rate, plus an applicable margin based on Abbott's credit ratings in effect from time to time. Abbott will also pay to the lenders under the Revolving Credit Agreement certain customary fees.

The Revolving Credit Agreement contains representations and warranties and affirmative and negative covenants customary for unsecured financings of this type as well as customary events of default.

The foregoing description of the Revolving Credit Agreement is qualified in its entirety by reference to the full text of the Revolving Credit Agreement, a copy of which will be filed with Abbott's Annual Report on Form 10-K for the year ended December 31, 2020.

Some of the lenders under the Revolving Credit Agreement and/or their respective affiliates have in the past performed, and may in the future from time to time perform, investment banking, financial advisory, lending and/or commercial banking services, or other services for Abbott and its subsidiaries, for which they have received, and may in the future receive, customary compensation and expense reimbursement.


Item 1.02.  Termination of a Material Definitive Agreement.


In connection with its entry into the Revolving Credit Agreement, on the Effective Date Abbott terminated all commitments outstanding under the Five Year Credit Agreement, dated November 30, 2018 (as in effect from time to time, the "Existing Credit Agreement"), among Abbott, the lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent. There were no outstanding borrowings under the Existing Credit Agreement at the time of its termination.

The Existing Credit Agreement provided Abbott with the ability to borrow up to $5 billion on an unsecured basis. Absent termination, any borrowings under the Existing Credit Agreement would have matured and been payable on November 30, 2023. Abbott's borrowings under the Existing Credit Agreement bore interest, at Abbott's option, based on either a base rate or a Eurodollar rate, plus an applicable margin based on Abbott's credit ratings in effect from time to time.

Some of the lenders under the Existing Credit Agreement and/or their respective affiliates have in the past performed, and may in the future from time to time perform, investment banking, financial advisory, lending and/or commercial banking services, or other services for Abbott and its subsidiaries, for which they have received, and may in the future receive, customary compensation and expense reimbursement.

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The disclosure contained in Item 1.01 is incorporated in this Item 2.03 by reference.




                                       2

© Edgar Online, source Glimpses

All news about ABBOTT LABORATORIES
06:37aABBOTT LABORATORIES : Receives expanded medicare reimbursement for first-of-its-..
AQ
01/20ABBOTT LABORATORIES : Says MitraClip Device to Receive Expanded Medicare Reimbur..
MT
01/20ABBOTT : Receives Expanded Medicare Reimbursement for First-Of-Its-Kind MitraCli..
PR
01/15ABBOTT LABORATORIES : To launch the neurosphere mypath digital health app design..
AQ
01/14ABBOTT : to Launch the NeuroSphere™ myPath™ Digital Health App Desig..
PR
01/14ABBOTT LABORATORIES : Ex-dividend day for
FA
01/13ABBOTT LABORATORIES : Announces fulfillment of federal government purchase of 15..
AQ
01/12ABBOTT LABORATORIES : Fulfills US Government's Order of 150 Million BinaxNOW COV..
MT
01/12ABBOTT : Announces Fulfillment of Federal Government Purchase of 150 Million Bin..
PR
01/11ABBOTT LABORATORIES : Receives FDA 510(k) Clearance for Rapid Handheld Blood Tes..
MT
More news
Financials (USD)
Sales 2020 33 854 M - -
Net income 2020 4 415 M - -
Net Debt 2020 11 794 M - -
P/E ratio 2020 46,1x
Yield 2020 1,28%
Capitalization 193 B 193 B -
EV / Sales 2020 6,06x
EV / Sales 2021 5,26x
Nbr of Employees 107 000
Free-Float 88,9%
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 119,94 $
Last Close Price 112,89 $
Spread / Highest target 19,6%
Spread / Average Target 6,25%
Spread / Lowest Target -27,4%
EPS Revisions
Managers and Directors
NameTitle
Robert B. Ford President, CEO, Chief Operating Officer & Director
Miles D. White Executive Chairman
Robert E. Funck Chief Financial Officer & Executive Vice President
Roxanne Schuh Austin Independent Director
Samuel C. Scott Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBOTT LABORATORIES3.11%193 426
MEDTRONIC PLC1.84%160 567
BECTON, DICKINSON AND COMPANY5.23%76 581
HOYA CORPORATION-5.57%48 658
ALIGN TECHNOLOGY, INC.5.61%44 501
BAXTER INTERNATIONAL INC.-0.90%40 620